Harry Jr. Thomasian Sells 171,429 Shares of Precigen (NASDAQ:PGEN) Stock

Precigen, Inc. (NASDAQ:PGEN) CFO Harry Jr. Thomasian sold 171,429 shares of Precigen stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $5.53, for a total value of $948,002.37. Following the completion of the sale, the chief financial officer directly owned 354,535 shares of the company’s stock, valued at approximately $1,960,578.55. The trade was a 32.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harry Jr. Thomasian also recently made the following trade(s):

• On Monday, June 29th, Harry Jr. Thomasian sold 28,571 shares of Precigen stock. The stock was sold at an average price of $5.78, for a total value of $165,140.38.
• On Thursday, May 28th, Harry Jr. Thomasian sold 41,884 shares of Precigen stock. The shares were sold at an average price of $4.36, for a total value of $182,614.24.

Precigen Trading Up 7.4%

Precigen stock opened at $5.64 on Friday. Precigen, Inc. has a one year low of $1.47 and a one year high of $6.04. The business’s fifty day moving average is $4.46 and its 200 day moving average is $4.24. The stock has a market capitalization of $2.01 billion, a PE ratio of -4.78 and a beta of 1.00. The company has a debt-to-equity ratio of 4.62, a current ratio of 4.82 and a quick ratio of 4.12.

Precigen (NASDAQ:PGEN) last issued its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The business had revenue of $23.25 million during the quarter, compared to analyst estimates of $20.81 million. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%. On average, sell-side analysts predict that Precigen, Inc. will post -0.02 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on PGEN shares. Citigroup restated an “outperform” rating on shares of Precigen in a report on Thursday, May 14th. Zacks Research raised shares of Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Wall Street Zen cut Precigen from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research note on Tuesday, April 21st. Finally, Citizens Jmp raised their price target on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $12.50.

Institutional Trading of Precigen

Several hedge funds have recently made changes to their positions in PGEN. Xponance LLC grew its stake in shares of Precigen by 21.3% during the fourth quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 2,496 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Precigen by 6.1% during the third quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock valued at $170,000 after buying an additional 2,993 shares during the period. Composition Wealth LLC increased its position in Precigen by 16.5% during the 4th quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 3,000 shares during the period. Intech Investment Management LLC raised its stake in Precigen by 5.2% in the fourth quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock worth $263,000 after buying an additional 3,137 shares in the last quarter. Finally, Cetera Investment Advisers raised its position in shares of Precigen by 0.9% in the 1st quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company’s stock worth $1,449,000 after acquiring an additional 3,250 shares in the last quarter. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.